Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Ovarian Neoplasms 45 Breast Neoplasms 39 Triple Negative Breast Neoplasms 19 Prostatic Neoplasms 17 Neoplasms 13 Fallopian Tube Neoplasms 13 Endometrial Neoplasms 12 Recurrence 8 Pancreatic Neoplasms 8 Neoplasm Metastasis 8 Squamous Cell Carcinoma of Head and Neck 7 Small Cell Lung Carcinoma 7 Lung Neoplasms 6 Carcinoma, Ovarian Epithelial 6 Glioma 5 Glioblastoma 5 Carcinoma, Renal Cell 5 Uterine Cervical Neoplasms 4 Sarcoma 4 Carcinoma, Squamous Cell 4 Carcinoma, Non-Small-Cell Lung 4 Advanced Breast Cancer 4 Stomach Neoplasms 3 Solid Tumor 3 Melanoma 3 Head and Neck Neoplasms 3 Fanconi Anemia, Complementation Group D1 3 Uveal Melanoma 2 Uterine Neoplasms 2 Urinary Bladder Neoplasms 2

Interventions

pembrolizumab 1 olaparib 1 Etoposide 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × SCLC,Extensive Stage × olaparib × Clear all

NCT05623319 2025-06-24

THOR

Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS

Phase 2 Recruiting

SCLC,Extensive Stage

Data powered by HemOnc (CC BY 4.0) Colophon ⚡